Glynib (Imatinib Mesilate) 100mg Capsules in Pakistan

Description

Glynib (Imatinib Mesylate) 100 mg Tablets – 120 Tablets | PharmaSol Pharmaceutical (Pvt) Ltd.

Brand Name: Glynib
Generic Name: Imatinib Mesylate
Dosage Strength: 100 mg
Manufacturer: PharmaSol Pharmaceutical (Pvt) Ltd.
Pack Size: 120 Tablets

Overview

Glynib (Imatinib Mesylate) 100 mg is an anticancer medication classified as a Tyrosine Kinase Inhibitor (TKI). It is specifically designed to target and block abnormal proteins responsible for the growth, survival, and multiplication of cancer cells. By inhibiting these abnormal tyrosine kinase enzymes, Glynib helps slow down or stop disease progression.

This medication is widely used as first-line therapy in several hematological and solid tumor malignancies and is considered a breakthrough treatment in cancers like Chronic Myeloid Leukemia (CML).

How Glynib (Imatinib Mesylate) Works

Cancer cells often rely on abnormal growth signals transmitted through tyrosine kinases. Glynib binds to specific tyrosine kinase receptors, including those associated with the BCR-ABL fusion gene and KIT protein, stopping the signal transmission that causes cancer cells to proliferate.

By blocking these pathways, Imatinib:

• Prevents cancer cell division

• Reduces tumor progression

• Helps improve blood counts and disease remission

Indications / Uses of Glynib Tablets

Glynib (Imatinib Mesylate) 100 mg is indicated for the treatment of:

1. Chronic Myeloid Leukemia (CML)

   • Effective in chronic phase, accelerated phase, and blast crisis

   • Used as initial therapy and for patients who are resistant or intolerant to previous treatments

2. Acute Lymphoblastic Leukemia (ALL)

   • Specifically for Philadelphia chromosome-positive (Ph+) ALL

   • Used in combination with chemotherapy as part of induction and maintenance therapy

3. Gastrointestinal Stromal Tumors (GISTs)

   • For treatment of unresectable or metastatic GISTs

   • Helps stabilize disease and shrink tumor mass

4. Dermatofibrosarcoma Protuberans (DFSP)

   • Used in unresectable, recurrent, or metastatic DFSP cases

   • Targets PDGF receptor tyrosine kinase involved in tumor growth

Glynib: Directions for Use

• Glynib should be taken exactly as prescribed by a healthcare professional.

• Typically taken once or twice daily with food and a full glass of water.

• Tablets should be swallowed whole; do not crush or chew unless instructed by a healthcare provider.

Possible Side Effects of Glynib:

Common side effects may include:

• Nausea, vomiting, or diarrhea

• Fluid retention (swelling around eyes or ankles)

• Muscle cramps and joint pains

• Fatigue or weakness

• Skin rash

Serious but less common side effects:

• Low blood cell counts (anemia, neutropenia, thrombocytopenia)

• Liver function abnormalities

• Severe fluid retention (including pleural or pericardial effusion)

• Heart problems (rare)

Seek medical help immediately if you experience:

• Shortness of breath

• Unusual bruising or bleeding

• Yellowing of skin or eyes (jaundice)

Storage Instructions

• Store at room temperature (below 25°C).

• Keep away from moisture and direct sunlight.

• Keep out of reach of children.

Disclaimer

• This product description is for informational purposes only and does not replace professional medical advice.

• Glynib (Imatinib Mesylate) is a prescription-only medicine and should be used strictly under the supervision of an oncologist or qualified physician.

• Do not adjust dosage or stop treatment without consulting your doctor.

• Side effects and treatment response vary from patient to patient.

• Product packaging, batch details, and appearance may vary depending on the manufacturer’s update.